DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Cronkhite-Canada syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCronkhite-Canada syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cronkhite-canada syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Cronkhite-Canada syndrome is a nonhereditary syndrome of unknown aetiology, characterised by diffuse gastrointestinal polyposis, the dermatological triad of nail dystrophy, hyperpigmentation and alopecia, and symptoms including diarrhoea, weight loss and abdominal pain. No definitive treatment is available; supportive and symptomatic care aim to improve symptoms and quality of life. Early diagnosis is emphasised to reduce morbidity and mortality, as the condition is often life-threatening.
One case report describes a late-onset patient who experienced relief after prednisone treatment. Another severe case demonstrated clinical and endoscopic response to corticosteroids, and that response was maintained with azathioprine, providing experience with a strategy to induce and maintain a durable corticosteroid-free remission. The literature on CCS consists mostly of case reports, and there is no consensus on management.
The evidence is limited to single-case observations. No controlled trials, no larger case series, and no data on response rates or survival in a defined cohort exist. The two cases that report benefit from corticosteroids and azathioprine cannot be generalised.
What is still missing is any systematic trial design, patient stratification, or funding to move beyond anecdotal reports. Without these, no reliable treatment recommendation can be made.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Digestive Endoscopy · 2020 · 1 citations · open access
Case of Cronkhite-Canada Syndrome
AbstractCronkhite–Canada syndrome is a nonhereditary syndrome. It is characterized by cutaneous manifestations and gastrointestinal (GI) polyps. Patients may also present with diarrhea and weight loss. Early diagnosis of disease is important to avoid morbidity and mortality. Definitive treatment is not available for Cronkhite–Canada syndrome but supportive care and symptomatic treatment will improve the symptoms and increase the quality of life.
World Journal of Clinical & Medical Images · 2023 · 0 citations · open access
Protein-Losing Enteropathy, Anasarca and Dermatological Manifestations on People of Advanced Age: Don't Overlook the Diagnostic Hypothesis of a Cronkhite Canada Syndrome
AbstractCronkhite-Canada syndrome is a rare and non-genetic syndrome of unknown etiology, characterized by diffuse gastrointestinal polyposis, the dermatological triad (nail distrophy, hyperpigmentation, alopecia), diarrhea, weight loss and abdominal pain. Herein, we describe a late-onset case that experienced relief after prednisone treatment. It is very important keep in mind the clinical hypothesis of this syndrome, because an early diagnosis can help reduce morbidity and mortality associated with this pathology, which is often life threatening
Journal of applied research in the community college · 1998 · 0 citations
Case Study Three: The Multiple Dimensions of Institutional Effectiveness: Faculty and Staff Views at an Urban Community College District.
AbstractCronkhite-Canada Syndrome (CCS) is a rare, sporadic polyposis condition. The literature on CCS consists mostly of case reports. Although disease presentation has been well-described, there is no consensus on the management of CCS. We present a severe case of CCS that demonstrated clinical and endoscopic response to corticosteroids. This response was maintained with azathioprine. This case provides additional experience on a therapeutic strategy to induce and maintain a durable corticosteroid-free remission.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
